These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24494810)

  • 1. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
    Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
    Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
    Noble CO; Krauze MT; Drummond DC; Yamashita Y; Saito R; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
    Cancer Res; 2006 Mar; 66(5):2801-6. PubMed ID: 16510602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
    Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
    Krauze MT; Noble CO; Kawaguchi T; Drummond D; Kirpotin DB; Yamashita Y; Kullberg E; Forsayeth J; Park JW; Bankiewicz KS
    Neuro Oncol; 2007 Oct; 9(4):393-403. PubMed ID: 17652269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
    Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
    Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
    Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
    J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered irinotecan metabolism in a patient receiving phenytoin.
    Mathijssen RH; Sparreboom A; Dumez H; van Oosterom AT; de Bruijn EA
    Anticancer Drugs; 2002 Feb; 13(2):139-40. PubMed ID: 11901305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
    Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
    Drummond DC; Noble CO; Guo Z; Hong K; Park JW; Kirpotin DB
    Cancer Res; 2006 Mar; 66(6):3271-7. PubMed ID: 16540680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
    Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
    J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
    Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
    Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
    Ko AH
    Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
    Buckner JC; Reid JM; Wright K; Kaufmann SH; Erlichman C; Ames M; Cha S; O'Fallon JR; Schaaf LJ; Miller LL
    Cancer; 2003 May; 97(9 Suppl):2352-8. PubMed ID: 12712456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.